The Harley Street Journal

Bi-monthly newspaper for the cosmetic and plastic surgery sector

dermal fillers

New Hyaluronic Acid filler launched

by

The new Hyaluronic Acid (HA) filler MaiLi, from Sinclair Pharma, launches 28thApril 2021.

The new product range harnesses the power of the world’s first OxiFree HA technology.

MaiLi is the natural partner for gifted professionals to refine their craft with precision and care, using the finest Swiss science to unlock the highest levels of aesthetic artistry.

The new HA filler offers supple volume, projection power and elasticity, allowing for natural movement. MaiLi Extreme is verified as a volumising and supple filler, with an unparalleled projection rate of 34% more than the market leader. 

Meanwhile, MaiLi Extreme uses 24% less gel for the same volumising effect, compared with the market leader – a brand where less filler means more fullness and flexibility.

Not only does less product mean more treatment possibilities for patients, but, for the same patient, practitioners can use the same syringe in multiple areas to exceed patient results, creating superior results which gradually build over time.

This premium HA gel is designed for the treatment of fine-lines, medium sized skin depressions, the periorbital area, volume loss, and is especially effective for lip definition or enhancement. 

MaiLi follows the lineage established by medical aesthetics company Sinclair Pharma which also boasts Ellansé, the first collagen stimulating dermal filler for the face, in its treatment portfolio; as well as the recently launched Lanluma dermal filler for the body and face, and Silhouette Soft, its unique cone threaded sutures for non-surgical skin lifting. 

For more information, please visit:  https://www.sinclairpharma.com

Research Shows 1 in 4 Men Having Dermal Fillers

by

According to new research a quarter of men are having dermal fillers to reward themselves.

Survey results showed that 18 per cent of the UK population would consider using hyaluronic acid dermal fillers for a number of reasons such as to stay youthful, remain competitive at work and to compliment weight loss.

Until now, 90 per cent of all aesthetic procedures have been carried out on women, however, Intraline’s research found that UK men are bucking the trend with 1 in 4 of male survey respondents having dermal fillers to reward themselves.

“Over the last 24 months, I have seen a definite increase in the number of men seeking natural, non-invasive treatments using hyaluronic acid fillers,” stated Dr. Olivier Amar, leading London-based Plastic Surgeon.

“The current trend is about maintaining the masculine features of the patient. Utilising products such as Intraline for Men has allowed me to treat a variety of patient concerns without changing their dynamic facial expression. Reducing the appearance of frown lines and nasolabial folds and augmenting the chin and jawline are the main treatments requested by men.”

Overtime, an individual stops naturally producing HA which creates the traditional signs of aging, such as drooping skin and wrinkles. Intraline for Men, a non-permanent treatment that can last on average 12 months, is designed to reduce these visible signs of aging by replacing the diminished HA and filling out the space below wrinkles, fine lines and cheek hollows.

Intraline’s Dermal Fillers have been developed utilising the finest ingredients and specifically formulated at a molecular level to provide the smoothest, most natural results available today.

Produced through a proprietary bacterial fermentation process and never animal-derived, Intraline’s Hyaluronic Acid is both effective and environmentally responsible. Following years of Swedish research, Intraline’s Dermal Fillers use innovative spherification technology, which smoothes HA’s traditionally angular rhomboid molecular structure.

This formulation technique provides Intraline’s fillers with some of the highest molecular densities of any product on the market today, leading to smoother, more natural results than ever before.

Intraline for Men is focused on treatment for deep-set wrinkles, facial contouring, mandible, frown lines, forehead lines, and much more. Injections are administered at the mid-dermis to deep-dermis level as the product consists of large molecular spheres.

It is non-animal derived and created through bacterial fermentation. It integrates naturally into the injected tissue, allowing oxygen and hormones to continue to easily pass through the tissue.

Intraline for Men uses a proprietary spherification technology to smooth HA’s traditionally rhomboid molecular structure providing Intraline’s fillers with some of the highest molecular density of any products on the market today.

“We want to dissolve the stereotypes and continue to support the idea that aesthetic treatments are not just for women,” Reece Tomlinson, CEO of Intraline Lifestyle Aesthetics commented.

“We pride ourselves on bringing a fresh perspective and continual innovation to aesthetic treatments through our commitment to provide safe and quality products with fantastic results. This is why we have created one of the first dermal fillers, if not the first, marketed to men.”

Statistics indicate that nearly a third of UK adults have received an aesthetic treatment for a change in job or career, underlining that youthfulness still equates to success in the workplace for many people.

Intraline for Men launched in the UK, February 2016. For more information visit www.intraline.com

Allergan Launches New Periorbital Treatment Protocol

by

12794953_xxlAllergan have unveiled a new treatment protocol for periorbital revitalisation which incorporates a portfolio combination approach of both BOTOX® and the VYCROSS™ Collection of dermal filler treatments.

Developed in consultation with twelve European expert medical aesthetics practitioners, the latest guidance describes an approach for treating this challenging facial region which is holistic, individualised and stepwise.

As part of Allergan’s ongoing commitment to excellence in medical education, the new treatment protocol will be launched to over 15,000 medical practitioners across Europe as part of an extensive $6 million training programme, which is led by one of the leading global surgeons, Dr Mauricio De Maio.

Market trends and insights continue to underline the high importance of this facial region for patients, as it often represents one of the first areas considered for a cosmetic injectable treatment. Recent market research shows that crow’s feet lines are the most desired area for a facial injectable treatment, with under-eye bags and glabellar lines following closely behind in the top six areas of ageing concern.

Latest results from a new European survey also show that people are least happy with their eye area (versus other facial zones) – this unhappiness is more prevalent among women and peaks around the age of 40.

The top ageing concerns for the eye area were identified as dark circles, wrinkles and under-eye bags.

 

However, the periorbital region can represent a treatment challenge due to the complex anatomy and the need for advanced injection techniques. With this in mind, and based on feedback from the clinical community, Allergan supported the development of a new treatment protocol which provides expert guidance on periorbital anatomy, patient assessment and a stepwise approach to achieving optimal treatment outcomes using Allergan’s portfolio combination of BOTOX® and the VYCROSS™ Collection.

Mr Kambiz Golchin, a Consultant ENT and Facial Plastic Surgeon, says in his clinical practice, he sees high numbers of patients who want to refresh their eye area and address key ageing concerns like eye bags and crow’s feet lines, but who are concerned about maintaining a natural looking result and keeping their expressions.

“This is where Allergan’s new periorbital treatment protocol can play a role in guiding physicians through the treatment options now available for this complex area, in order to deliver results which reflect patients’ unique characteristics, ethnicity and personal treatment goals,” he explains.

“Expert training is key to ensuring these treatments are used correctly to deliver optimal results for patients.”

Allergan is a multi‐specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative treatments and an evolving portfolio of pharmaceuticals, biologics, medical devices and over‐the‐counter consumer products.